Bluefield increases dividend in bid to rerate shares
Manager James Armstrong said the 8.6p-per-share, full-year dividend, which was 0.2p above target, and the long-term visibility of earnings should narrow the discount.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
ThomasLloyd Energy hires Octopus to bring it back from suspension
Suspended renewables fund picks manager of rival Octopus Renewables Infrastructure to run its portfolio until next April after sacking ThomasLloyd Global Asset Management.
Longbow revalues loans as property and debt markets deteriorate
The £33m trust said UK commercial property market conditions had made its managed wind-down difficult as high interest rates and high inflation impacted property transaction volumes.
Pantheon Infrastructure shifts to capital management as dividend cover raises concerns
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
Pantheon shifts to capital management as dividend cover raises concerns
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
Boss of one-time Woodford-favourite biotech leaves amid strategic review
Arix Bioscience chief executive Robert Lyne departs midway through a strategic review with the shares trading at a 38% discount.
Exiting Symphony finally plays tune that shareholders want
Symphony International, a badly-performing Asia private equity fund, announces ‘orderly realisation’ of its assets after failing to revive its heavily discounted share price.
Aurora offers fee-free rally but Buffett disciple not yet ‘raining gold’
Garry Channon's unusual Netflix-holding UK value fund stages first half turnaround despite its new position in Hotel Chocolat suffering a share price meltdown.
Floating rate loans boost BioPharma Credit earnings
The dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, however, problems with LumiraDx continue to be a concern for analysts.
BioPharma's solid results overshadowed by distressed LumiraDX loan
Dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, but problems with LumiraDx continue to concern analysts.
BioPharama's solid results overshadowed by distressed LumiraDX loan
Dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, but problems with LumiraDx continue to concern analysts.
Abrdn’s closure of investment trust saving plans angers investors
Abrdn is closing its historic investment trust savings plans and annoying investors with the transfer of their holdings to Interactive Investor, the online stockbroker it owns.
